The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
30. June 2026
The two EU-HTA procedures for the active substances catequentinib and Tacquell have been closed. The central issue is Article 9 of Regulation (EU) 2021/2282.
Article 9 requires an EU-HTA dossier …
18. June 2026
Prof. Josef Hecken today chaired a plenary session as impartial chair of the G-BA for the last time. Since 2012, and thus for almost the entire period since the introduction …
12. June 2026
Berlin, 12 June 2026 – The Third Ordinance amending the Medicinal Products Pricing Ordinance (AMPreisV) has been in force since 12 June 2026. The ordinance implements the coalition agreement and, …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
